Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II). 1979

R J Belt, and K J Himmelstein, and T F Patton, and S J Bannister, and L A Sternson, and A J Repta

The pharmacokinetics of non-protein-bound platinum species derived from cis-dichlorodiammineplatinum(II) (cis-platinum) was studied under a variety of dosing conditions. Following rapid infusions (15-minute) of cis-platinum at 100 mg/m2, the unbound drug declined in a biphasic mode with a mean terminal half-life of 48 minutes. The mean beta-phase half-life after a 6-hour infusion of the same dose of cis-platinum was 26 minutes. Urinary excretion of filterable platinum was substantially greater after a 6-hour infusion than after a 15-minute injection. Concomitant administration of mannitol appeared to result in higher peak plasma concentrations and decreased urinary excretion of unbound platinum species but did not alter the terminal half-life. Renal impairment was associated with extremely high plasma levels of filterable platinum but did not affect other pharmacokinetic parameters. Preliminary data on the distribution of cis-platinum to ascitic fluid are also presented.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008353 Mannitol A diuretic and renal diagnostic aid related to sorbitol. It has little significant energy value as it is largely eliminated from the body before any metabolism can take place. It can be used to treat oliguria associated with kidney failure or other manifestations of inadequate renal function and has been used for determination of glomerular filtration rate. Mannitol is also commonly used as a research tool in cell biological studies, usually to control osmolarity. (L)-Mannitol,Osmitrol,Osmofundin
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001202 Ascitic Fluid The serous fluid of ASCITES, the accumulation of fluids in the PERITONEAL CAVITY. Peritoneal Effusion,Peritoneal Fluid,Ascitic Fluids,Effusion, Peritoneal,Fluid, Ascitic,Fluid, Peritoneal,Peritoneal Effusions,Peritoneal Fluids

Related Publications

R J Belt, and K J Himmelstein, and T F Patton, and S J Bannister, and L A Sternson, and A J Repta
April 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
R J Belt, and K J Himmelstein, and T F Patton, and S J Bannister, and L A Sternson, and A J Repta
January 1979, Cancer treatment reports,
R J Belt, and K J Himmelstein, and T F Patton, and S J Bannister, and L A Sternson, and A J Repta
January 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
R J Belt, and K J Himmelstein, and T F Patton, and S J Bannister, and L A Sternson, and A J Repta
June 1982, Cancer treatment reviews,
R J Belt, and K J Himmelstein, and T F Patton, and S J Bannister, and L A Sternson, and A J Repta
June 1978, Clinical chemistry,
R J Belt, and K J Himmelstein, and T F Patton, and S J Bannister, and L A Sternson, and A J Repta
October 1975, Cancer research,
R J Belt, and K J Himmelstein, and T F Patton, and S J Bannister, and L A Sternson, and A J Repta
September 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
R J Belt, and K J Himmelstein, and T F Patton, and S J Bannister, and L A Sternson, and A J Repta
May 1979, Journal of chromatography,
R J Belt, and K J Himmelstein, and T F Patton, and S J Bannister, and L A Sternson, and A J Repta
January 1979, Cancer treatment reports,
R J Belt, and K J Himmelstein, and T F Patton, and S J Bannister, and L A Sternson, and A J Repta
February 1985, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!